# Shlomi Madar

> Shlomi Madar is the CEO of SpotitEarly, an Englewood, New Jersey biotech developing a non-invasive, breath-based multi-cancer screening test that pairs trained scent-detection dogs with a deep-learning platform. He holds a PhD in cancer research from the Weizmann Institute of Science and has spent more than fifteen years in life sciences and healthcare, previously serving as VP of Strategic Alliances at OncoHost and working on the Weizmann Institute's innovation arm. In May 2025 SpotitEarly closed a $20.3M Series A behind clinical results the company reports at roughly 94% sensitivity and specificity across four cancer types.

- **Role:** CEO & Board Member at SpotitEarly
- **Organizations:** SpotitEarly, OncoHost, Weizmann Institute of Science, RightQ Consulting
- **From:** Israel
- **Nationality:** Israeli
- **Education:** PhD, Molecular Cell Biology (cancer research), Weizmann Institute of Science
- **Known for:** Leads SpotitEarly, developer of a breath-based, bio-AI hybrid cancer screening platform, Closed a $20.3M Series A in May 2025 (~$34.3M total raised), Oversaw the Rainbow Study, reporting 93.9% sensitivity and 94.3% specificity across four cancers

## Career timeline

- **2006-2012** — PhD in cancer research at the Weizmann Institute, under Prof. Varda Rotter
- **2010s** — Consulting and business development roles across life sciences (RightQ Consulting)
- **prior** — Consultant with the Weizmann Institute's innovation arm, East Coast
- **prior** — Vice President, Strategic Alliances at OncoHost
- **prior** — Vice President, Business Development (North America) at SpotitEarly
- **current** — CEO & Board Member, SpotitEarly
- **2025-05** — SpotitEarly closes $20.3M Series A; total funding ~$34.3M
- **2025-05** — Presented at BioNJ's BioPartnering Conference, Jersey City

## Achievements

- Leads SpotitEarly, developer of a breath-based, bio-AI hybrid cancer screening platform
- Closed a $20.3M Series A in May 2025 (~$34.3M total raised)
- Oversaw the Rainbow Study, reporting 93.9% sensitivity and 94.3% specificity across four cancers
- PhD from the Weizmann Institute of Science with peer-reviewed publications in cancer biology

## Latest updates

- **2025-05** — SpotitEarly announced a $20.3M Series A
- **2025-05** — Presented at BioNJ's BioPartnering Conference in Jersey City
- **2025-03** — Interview published in Authority Magazine on Medium

## Links

- Website: https://spotitearly.com
- LinkedIn: https://www.linkedin.com/in/shlomimadar/

---

Profile page: https://yespress.io/shlomi-madar
Published by YesPress — https://yespress.io
Last updated: 2026-07-08